display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer - HER2-positivebreast cancer - HR positivebreast cancer - triple negative
es-BC - HER2 positive - (neo)adjuvant (NA)la/mBC - HR positivemBC - Triple negative (TNBC) - 1st Line (L1)es-BC - TNBC - NA - all population
non platinum-based chemotherapy
microtubul inhibitor
eribulin NCT03051659
taxanes
paclitaxel
nab-paclitaxel TORCHLIGHT TORCHLIGHT
paclitaxel followed by doxorubicin plus cyclophosphamide IMpassion-050 IMpassion-050 IMpassion-050 ALEXANDRA/IMpassion-030

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons